Recent Updates — CPIX
Cumberland Pharmaceuticals announced it will submit a New Drug Application (NDA) to the FDA for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The decision follows a pre-NDA meeting with the FDA in October 2026. The submission will rely on data from the Phase 2 FIGHT DMD trial, which showed a statistically significant 5.4% absolute improvement in left ventricular ejection fraction compared to controls, along with open-label extension data and natural history databases. The FDA granted rolling review status for the application but expressed concerns regarding the sufficiency of the data package for approval. Cumberland Pharmaceuticals is an innovation-focused biopharmaceutical company developing new therapies to address significant unmet medical needs.
On October 23, 2026, Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. The results support the safety and tolerability of ifetroban in this rare disease population. Cumberland Pharmaceuticals Inc. operates as a biopharmaceutical company focused on developing treatments for rare diseases.
Cumberland Pharmaceuticals Inc. reported Q2 2026 financial results and announced the closing of a strategic transaction with Apotex Health on July 1, 2026. Under the agreement, Apotex acquired Cumberland’s portfolio of FDA-approved brands for $100 million in cash plus $11 million for inventory and transition services. Following this divestiture, Cumberland is transitioning to a development-stage biopharmaceutical organization focused on rare diseases. The company declared a special cash dividend of $1.50 per share, paid on July 31, 2026, to shareholders of record as of July 23, 2026. For the quarter ended June 30, 2026, Cumberland reported a net loss of $4.1 million, including a $3.1 million loss from continuing operations and $1.0 million from discontinued operations. At quarter-end, the company held approximately $4 million in cash and total assets of $62.9 million. Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing late-stage clinical candidates for rare diseases.
Cumberland Pharmaceuticals Inc. declared a special cash dividend of $1.50 per share, payable on or about July 31, 2026, to shareholders of record as of July 23, 2026. This decision follows a strategic transaction with Apotex Health Corp. that resulted in $100 million in cash at closing, with an additional $11 million expected. The Board also authorized a $5 million open-market share repurchase program. Cumberland Pharmaceuticals Inc. is a pharmaceutical company that develops and commercializes FDA-approved products.